产品名称
抗 葡萄糖脑苷脂酶(C 端) 兔抗, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
antigen ~60 kDa
species reactivity
human, mouse, rat
packaging
antibody small pack of 25 μL
enhanced validation
recombinant expression
Learn more about Antibody Enhanced Validation
concentration
~1 mg/mL
technique(s)
western blot: 1-2 μg/mL using HEK293-T cells lysate expressing human glucocerebrosidase (GBA)
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... GBA(2629)
mouse ... Gba(14466)
Application
家兔的抗葡萄糖脑苷脂酶(C末端)抗体可用于
- 免疫组化
- 免疫印迹分析
抗葡萄糖脑苷脂酶(C 端)抗体可用于蛋白质免疫印迹法 和免疫印迹法。
Biochem/physiol Actions
在GBA基因突变的人体内葡萄糖脑苷脂酶(GBA)活性降低,并导致葡萄糖神经酰胺(GlcCer)积累。来自特定GBA突变患者的成纤维细胞在内质网中有延迟或阻滞GBA运输的作用。人GBA基因的突变可能有助于常见年龄相关痴呆症(即路易氏体痴呆症)的发展。多项研究表明,人GBA基因的突变与早发性帕金森病有关。
葡糖脑苷脂酶是一种具有葡糖神经酰胺酶活性的酶。溶酶体水解酶葡糖脑苷脂酶缺陷导致戈谢病。GBA 的突变将阻碍或阻碍 GBA 向内质网的转运。
Disclaimer
除非我们的产品目录或产品附带的其他公司文档另有说明,否则我们的产品仅供研究使用,不得用于任何其他目的,包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
General description
葡萄糖脑苷酶是一种具有葡萄糖神经酰胺酶活性的酶。戈谢病的病因是溶酶体水解酶葡萄糖脑苷酶缺陷。GBA突变会延缓或阻断GBA向内质网的转运。 抗葡萄糖脑苷酶(c端)抗体可用来孵育SDS-PAGE凝胶。抗葡萄糖脑苷酶抗体对人GBA有特异性反应。
Immunogen
相应的于人葡糖脑苷脂酶 (GBA) 氨基酸 517-536 的合成肽,与 KLH 偶联。该序列在大鼠 GBA 中完全相同,在小鼠 GBA(单氨基酸替换)中高度保守。
Other Notes
Physical form
溶于含 15 mM 叠氮化钠的 0.01 M 磷酸盐缓冲盐水 (pH 7.4) 中。
未找到合适的产品?
试试我们的产品选型工具.
存储类别
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)
法规信息
常规特殊物品
此项目有
Nahid Tayebi et al.
Molecular genetics and metabolism, 122(4), 198-208 (2017-11-28)
Mutations in GBA1 encountered in Gaucher disease are a leading risk factor for Parkinson disease and associated Lewy body disorders. Many GBA1 mutation carriers, especially those with severe or null GBA1 alleles, have earlier and more progressive parkinsonism. To model
Inna Bendikov-Bar et al.
Orphanet journal of rare diseases, 9, 86-86 (2014-06-18)
Parkinson's disease (PD) is a movement neurodegenerative disorder characterized by death of dopaminergic neurons in the substantia nigra pars compacta of the brain that leads to movement impairments including bradykinesia, resting tremor, postural instability and rigidity. Mutations in several genes
Eun-Jin Bae et al.
Nature communications, 5, 4755-4755 (2014-08-27)
Deposition of α-synuclein aggregates occurs widely in the central and peripheral nervous systems in Parkinson's disease (PD). Although recent evidence has suggested that cell-to-cell transmission of α-synuclein aggregates is associated with the progression of PD, the mechanism by which α-synuclein
N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease
Garcia-Sanz P, et al.
Movement Disorders, 32(10), 1409-1422 (2017)
Lysosomal enzyme glucocerebrosidase protects against Abeta1-42 oligomer-induced neurotoxicity
Choi S, et al.
Testing, 10(12), e0143854-e0143854 (2015)
相关内容
Instructions
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持